Arcutis Biotherapeutics (ARQT) News Today $13.42 +0.43 (+3.31%) Closing price 04:00 PM EasternExtended Trading$13.56 +0.15 (+1.08%) As of 06:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Arcutis to Present at the TD Cowen 45th Annual Health Care ConferenceFebruary 18 at 4:35 PM | globenewswire.comArcutis Biotherapeutics (ARQT) to Release Quarterly Earnings on TuesdayArcutis Biotherapeutics (NASDAQ:ARQT) will be releasing earnings before the market opens on Tuesday, February 25, Financial Modeling Prep reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=656154)February 18 at 4:37 AM | marketbeat.comArcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Given Average Recommendation of "Moderate Buy" by BrokeragesFebruary 15, 2025 | americanbankingnews.comArcutis Biotherapeutics Becomes Oversold (ARQT)February 13, 2025 | nasdaq.comArcutis Biotherapeutics (NASDAQ:ARQT) Stock Price Down 9.5% - Here's WhyArcutis Biotherapeutics (NASDAQ:ARQT) Trading Down 9.5% - Here's WhyFebruary 13, 2025 | marketbeat.comArcutis Biotherapeutics jumps amid takeover speculationFebruary 12, 2025 | msn.comArcutis Biotherapeutics rumor highlighted in Betaville alertFebruary 12, 2025 | markets.businessinsider.comArcutis Biotherapeutics (NASDAQ:ARQT) Stock Price Up 20% - Still a Buy?Arcutis Biotherapeutics (NASDAQ:ARQT) Stock Price Up 20% - Time to Buy?February 12, 2025 | marketbeat.comFishman Jay A Ltd. MI Raises Stake in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)Fishman Jay A Ltd. MI boosted its holdings in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) by 28.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 536,400 shares of the company'sFebruary 12, 2025 | marketbeat.comArcutis Biotherapeutics (NASDAQ:ARQT) Given "Buy" Rating at GuggenheimFebruary 11, 2025 | americanbankingnews.comArcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesArcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the six research firms that are presently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and five haveFebruary 10, 2025 | marketbeat.comArcutis Biotherapeutics' (ARQT) Buy Rating Reaffirmed at GuggenheimGuggenheim reiterated a "buy" rating on shares of Arcutis Biotherapeutics in a research report on Monday.February 10, 2025 | marketbeat.comArcutis Biotherapeutics (NASDAQ:ARQT) Trading Down 7.7% - Time to Sell?Arcutis Biotherapeutics (NASDAQ:ARQT) Shares Down 7.7% - Here's WhyFebruary 7, 2025 | marketbeat.comArcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)February 5, 2025 | globenewswire.comArcutis Biotherapeutics exec sells $27,597 in stockFebruary 5, 2025 | msn.comArcutis Biotherapeutics' senior VP Matsuda sells $105,892 in stockFebruary 5, 2025 | msn.comArcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Insider Sells $105,892.60 in StockFebruary 5, 2025 | insidertrades.comInsider Selling: Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Insider Sells 8,338 Shares of StockArcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Get Free Report) insider Masaru Matsuda sold 8,338 shares of the company's stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $12.70, for a total transaction of $105,892.60. Following the completion of the sale, the insider now owns 178,692 shares in the company, valued at approximately $2,269,388.40. This trade represents a 4.46 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.February 4, 2025 | marketbeat.comInsider Selling: Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Director Sells 10,000 Shares of StockArcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Get Free Report) Director Howard G. Welgus sold 10,000 shares of the business's stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $12.71, for a total transaction of $127,100.00. Following the sale, the director now owns 141,944 shares of the company's stock, valued at approximately $1,804,108.24. This represents a 6.58 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.February 4, 2025 | marketbeat.comOdell Beckham Jr. and Arcutis Tackle Seborrheic Dermatitis in a "Clear Win for Your Skin"February 4, 2025 | prnewswire.comPositive Outlook for Arcutis Biotherapeutics Despite Temporary Prescription DeclinesFebruary 3, 2025 | markets.businessinsider.comJennison Associates LLC Acquires 676,295 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)Jennison Associates LLC grew its holdings in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) by 5.8% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 12,339,792 shares of the company's stock after buying an additiFebruary 3, 2025 | marketbeat.comShort Interest in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Declines By 9.3%Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Get Free Report) saw a large decrease in short interest in January. As of January 15th, there was short interest totalling 20,970,000 shares, a decrease of 9.3% from the December 31st total of 23,110,000 shares. Based on an average daily volume of 2,050,000 shares, the short-interest ratio is currently 10.2 days.January 31, 2025 | marketbeat.comArcutis Biotherapeutics Receives Buy Rating Amid Positive Sales Projections and GrowthJanuary 30, 2025 | markets.businessinsider.comArcutis Biotherapeutics (NASDAQ:ARQT) Stock Price Up 6.8% - What's Next?Arcutis Biotherapeutics (NASDAQ:ARQT) Shares Up 6.8% - Still a Buy?January 27, 2025 | marketbeat.comArcutis to Present at the Guggenheim SMID Cap Biotech ConferenceJanuary 27, 2025 | markets.businessinsider.comArcutis Biotherapeutics Receives Buy Rating Amid Strong Prescription Growth in Zoryve FranchiseJanuary 27, 2025 | markets.businessinsider.comZweig DiMenna Associates LLC Buys New Stake in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)Zweig DiMenna Associates LLC purchased a new position in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 41,500 shares of the company's stockJanuary 24, 2025 | marketbeat.comArcutis Biotherapeutics: After Outstanding 2024, Shares May Face Cooling Off PeriodJanuary 24, 2025 | seekingalpha.comStrong Prescription Growth for Arcutis Biotherapeutics’ Zoryve Franchise Supports Buy RatingJanuary 20, 2025 | markets.businessinsider.comShort Interest in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Decreases By 9.3%Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Get Free Report) saw a significant drop in short interest in December. As of December 31st, there was short interest totalling 20,970,000 shares, a drop of 9.3% from the December 15th total of 23,110,000 shares. Based on an average daily trading volume, of 2,050,000 shares, the days-to-cover ratio is presently 10.2 days.January 17, 2025 | marketbeat.comArcutis Biotherapeutics (NASDAQ:ARQT) Trading Down 4% - Here's WhyArcutis Biotherapeutics (NASDAQ:ARQT) Stock Price Down 4% - Time to Sell?January 17, 2025 | marketbeat.comArcutis Biotherapeutics’ Robust Revenue Growth and Strategic Financial Positioning Underpin Buy RatingJanuary 14, 2025 | markets.businessinsider.comTD Cowen Remains a Buy on Arcutis Biotherapeutics (ARQT)January 13, 2025 | markets.businessinsider.comArcutis Biotherapeutics price target raised to $20 from $18 at NeedhamJanuary 13, 2025 | markets.businessinsider.comArcutis Biotherapeutics (NASDAQ:ARQT) Shares Gap Up - Still a Buy?Arcutis Biotherapeutics (NASDAQ:ARQT) Shares Gap Up - Still a Buy?January 13, 2025 | marketbeat.comArcutis Shares Climb on Strong Product Revenue EstimatesJanuary 13, 2025 | marketwatch.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Hologic (HOLX) and Arcutis Biotherapeutics (ARQT)January 13, 2025 | markets.businessinsider.comStrong Financial Performance and Growth Prospects Drive Buy Rating for Arcutis BiotherapeuticsJanuary 13, 2025 | markets.businessinsider.comDemystifying Arcutis Biotherapeutics: Insights From 5 Analyst ReviewsJanuary 13, 2025 | benzinga.comHC Wainwright Reaffirms Buy Rating for Arcutis Biotherapeutics (NASDAQ:ARQT)HC Wainwright reaffirmed a "buy" rating and issued a $19.00 target price on shares of Arcutis Biotherapeutics in a report on Monday.January 13, 2025 | marketbeat.comArcutis Biotherapeutics reports preliminary Q4 revenue $63M, consensus $54.95MJanuary 12, 2025 | markets.businessinsider.comArcutis Biotherapeutics Projects Surge In Q4 Revenue GrowthJanuary 12, 2025 | markets.businessinsider.comArcutis Announces Preliminary Unaudited Fourth Quarter Product Revenue and Full-Year 2024 Product Revenues of Approximately $63 Million and $160 MillionJanuary 12, 2025 | globenewswire.comArcutis Biotherapeutics (NASDAQ:ARQT) Trading Down 8.5% - Here's What HappenedArcutis Biotherapeutics (NASDAQ:ARQT) Shares Down 8.5% - Here's What HappenedJanuary 10, 2025 | marketbeat.comArcutis Biotherapeutics price target raised to $20 from $19 at MizuhoJanuary 8, 2025 | markets.businessinsider.comMizuho Forecasts Strong Price Appreciation for Arcutis Biotherapeutics (NASDAQ:ARQT) StockMizuho increased their target price on shares of Arcutis Biotherapeutics from $19.00 to $20.00 and gave the company an "outperform" rating in a research report on Tuesday.January 7, 2025 | marketbeat.comArcutis Biotherapeutics (NASDAQ:ARQT) Hits New 52-Week High - What's Next?Arcutis Biotherapeutics (NASDAQ:ARQT) Reaches New 1-Year High - Time to Buy?January 7, 2025 | marketbeat.comArcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Director Howard G. Welgus Sells 10,000 SharesJanuary 7, 2025 | insidertrades.comArcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)January 6, 2025 | globenewswire.com Get Arcutis Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ARQT and its competitors with MarketBeat's FREE daily newsletter. Email Address ARQT Media Mentions By Week ARQT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ARQT News Sentiment▼0.290.58▲Average Medical News Sentiment ARQT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ARQT Articles This Week▼46▲ARQT Articles Average Week Get Arcutis Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ARQT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies BPMC News Today TLX News Today ELAN News Today LNTH News Today NUVL News Today CYTK News Today VRNA News Today GRFS News Today TGTX News Today KRYS News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ARQT) was last updated on 2/20/2025 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredEx-CIA Advisor: Trump 2.0 Could “Send Gold to $10,000”Experts forecast gold's price racing to $4,000… and an ex-CIA advisor predicts we'll see gold hit $10,000. ...Colonial Metals | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredAlert: DOGE goes live"It's Elon's world, and the rest of us live in it." Every investor in America is trying to figure out what ...Altimetry | SponsoredFeb. 26 Could Send Nvidia’s “Silent Partners” SoaringNvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | SponsoredMajor AI announcement for 2025BIG NEWS: “Market Wizard” Larry Benedict Releases a Whole New Way to Trade AI StocksBrownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcutis Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcutis Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ARQT Stock Alerts